Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Infiltrating Bladder Urothelial Carcinoma Clinical Trial

Official title:

Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02944357
• Other study ID #: MC1452
• Secondary ID: NCI-2016-01517MC
• Status: Withdrawn
• Phase: N/A
• First received: October 19, 2016
• Last updated: November 14, 2017
• Start date: November 2016
• Est. completion date: September 5, 2017

Study information

• Verified date: October 2016
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot clinical trial studies how well gemcitabine hydrochloride, cisplatin, and AGS-003-BLD work in treating patients with bladder cancer that has spread to the muscle and who are undergoing surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. Giving gemcitabine hydrochloride, cisplatin, and AGS-003-BLD before surgery may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery.

Description:

PRIMARY OBJECTIVES:

I. To assess the immunogenicity of AGS-003-BLD in subjects with muscle invasive bladder cancer.

SECONDARY OBJECTIVES:

I. To assess 1-year disease-free survival rate of patients with muscle-invasive bladder cancer who receive cisplatin/gemcitabine chemotherapy plus AGS-003-BLD.

II. To determine the time to first metastatic lesion. III. To explore the disease-free and overall survival of patients treated with this treatment combination.

IV. To evaluate the pathologic complete response (pCR) rate and identify any activity of this treatment combination.

V. To evaluate toxicities and tolerability associated with this treatment combination.

VI. To assess the success rate of tumor procurement and AGS-003-BLD production of >= 5 doses.

TERTIARY OBJECTIVES:

I. To evaluate the relationships between pathologic complete response with the change in CD28+ T cell levels.

II. To evaluate the change in frequency of CD11a highPD-1+ CD8+ T cells (and their expression of Bim) in peripheral blood.

OUTLINE:

NEOADJUVANT PHASE: Patients receive gemcitabine hydrochloride intravenously (IV) on days 1 and 8, AGS-003-BLD intradermally (ID) on day 1, and cisplatin IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive AGS-003-BLD ID on day 1. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

SURGERY: Patients undergo cystectomy during course 8.

ADJUVANT PHASE: Patients continue AGS-003-BLD ID on day 1 of course 9. Treatment repeats every 12 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 5, 2017
• Est. primary completion date: September 5, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• PRE-REGISTRATION INCLUSION CRITERIA: Diagnosis or clinical signs of urothelial carcinoma with clinical stage T2 or greater disease without lymph node involvement where neoadjuvant chemotherapy of cisplatin and gemcitabine are indicated

• PRE-REGISTRATION INCLUSION CRITERIA: Scheduled for a transurethral resection of bladder tumor (TURBT)

• PRE-REGISTRATION INCLUSION CRITERIA: Be a candidate for radical cystectomy

• PRE-REGISTRATION INCLUSION CRITERIA: Signed and dated informed consent document for study participation

• PRE-REGISTRATION INCLUSION CRITERIA: Willing to submit tissue for required correlative research

• REGISTRATION INCLUSION CRITERIA

• TURBT successfully completed

• Verification received from Argos Therapeutics that ribonucleic acid (RNA) successfully collected from TURBT procedure

• Be a candidate for radical cystectomy

• Diagnosis of urothelial carcinoma with stage T2 or greater disease without lymph node involvement where neoadjuvant chemotherapy of cisplatin and gemcitabine are indicated

• Absolute neutrophil count (ANC) >= 1500/uL

• Platelet count >= 100,000/uL

• Total bilirubin =< 1.5 x institutional upper normal limit (UNL) or =< 3 x institutional UNL if known Gilbert's syndrome

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x UNL

• Alkaline phosphatase =< 5 x UNL

• Hemoglobin >= 9.0 g/dL

• International normalized ratio (INR) and partial thromboplastin time (PTT) =< 3.0 x UNL; NOTE: anticoagulation is allowed if target INR =< 3.0 x UNL on a stable dose of warfarin or on a stable dose of low molecular weight heparin for > 2 weeks at time of registration

• Calculated creatinine clearance must be >= 50 ml/min using the applicable Cockcroft-Gault formula

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

• Ability to provide written informed consent

• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

• Willing to provide tissue and blood samples for correlative research purposes

• Negative serum pregnancy test for female subjects with reproductive potential =< 7 days prior to registration, for women of childbearing potential only

• Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study

Exclusion Criteria:

• RE-REGISTRATION EXCLUSION CRITERIA

• Requirement for systemic chronic immunosuppressive drugs or systemic chronic corticosteroids for active autoimmune disorder(s) or other conditions (e.g.: rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, organ transplant recipient, etc.)

• Known inability to undergo neoadjuvant gemcitabine and cisplatin combination treatment due to pre-existing medical conditions in the opinion of the treating physician or investigator

• Immunotherapy =< 28 days prior to pre-registration (e.g. intravesical Bacillus Calmette-Guerin [BCG])

• Any of the following prior therapies:

• Systemic chemotherapy for bladder cancer at any time; NOTE: intravesical chemotherapy is allowed

• Systemic chemotherapy for other malignancies =< 3 years prior to pre-registration

• REGISTRATION EXCLUSION CRITERIA

• Lymph node positive urothelial carcinoma

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator

• Treatment with oral/systemic corticosteroids =< 14 days prior to registration, with the exception of topical or inhaled steroids or steroids given for the purpose of antiemetics during chemotherapy

• New York Heart Association classification III or IV congestive heart failure

• Central nervous system (CNS) metastases or seizure disorder

• Any of the following:

• Pregnant women

• Nursing women

• Men or women of childbearing potential who are unwilling to employ adequate contraception

• Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) with the exception of intravesical therapy at the time of TURBT

• Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

• Clinically significant infections including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or C

• Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm

• Prior history of malignancy =< 3 years prior to registration, except for adequately treated non-melanoma skin cancer, adequately treated early stage breast cancer, adequately treated cervical cancer and non-metastatic prostate cancer under clinical control as deemed by treating physician or investigator

• History of myocardial infarction =< 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

• History of major surgery or traumatic injury =< 28 days prior to registration or other major anticipated procedures requiring general anesthesia during study participation

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Transitional Cell
• Infiltrating Bladder Urothelial Carcinoma
• Stage II Bladder Urothelial Carcinoma
• Stage III Bladder Urothelial Carcinoma
• Stage IV Bladder Urothelial Carcinoma
• Urinary Bladder Neoplasms

Intervention

Drug:
• Cisplatin
Given IV
• Gemcitabine Hydrochloride
Given IV

Procedure:
• Radical Cystectomy
Undergo cystectomy

Biological:
• Tumor Cell-Derived Vaccine Therapy
Given AGS-003-BLD ID

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in CD28 + T cell level with pathological complete response	Descriptive statistics (mean, sd, median, iqr) and longitudinal plots (raw value, change, and change in percentage) will be used to summarize the correlative endpoints. Further analysis will depend on the amount of data received and will be mainly exploratory.	Baseline up to 2 years
Other	Change in frequency of CD11a high PD-1+ CD8+ T cells (and their expression of Bim) in peripheral blood	Descriptive statistics (mean, sd, median, iqr) and longitudinal plots (raw value, change, and change in percentage) will be used to summarize the correlative endpoints. Further analysis will depend on the amount of data received and will be mainly exploratory.	Baseline up to 2 years
Primary	Change in the frequency of CD11a high PD-1+ CD8+ T cells	Descriptive statistics (mean, standard deviation [sd], median, interquartile range [iqr]) will be used to summarize change from baseline in the frequency of CD11a high PD-1+ CD8+ T cells following five doses of AGS-003-BLD.	Baseline, before systemic therapy with chemotherapy
Primary	Change in the frequency of CD11a high PD-1+ CD8+ T cells	Descriptive statistics (mean, standard deviation [sd], median, interquartile range [iqr]) will be used to summarize change from baseline in the frequency of CD11a high PD-1+ CD8+ T cells following five doses of AGS-003-BLD.	Prior to 1st dose of AGS-003-Bladder therapy
Primary	Change in the frequency of CD11a high PD-1+ CD8+ T cells	Descriptive statistics (mean, standard deviation [sd], median, interquartile range [iqr]) will be used to summarize change from baseline in the frequency of CD11a high PD-1+ CD8+ T cells following five doses of AGS-003-BLD.	Treatment visit 7 (Cycle 3) After 3rd dose of AGS-003-Bladder therapy, up to 7 days
Primary	Change in the frequency of CD11a high PD-1+ CD8+ T cells	Descriptive statistics (mean, standard deviation [sd], median, interquartile range [iqr]) will be used to summarize change from baseline in the frequency of CD11a high PD-1+ CD8+ T cells following five doses of AGS-003-BLD.	Treatment visit 15 (Cycle 6) - After the 5th dose of neoadjuvant AGS-003-Bladder therapy, up to 14 days
Primary	Change in the frequency of CD11a high PD-1+ CD8+ T cells	Descriptive statistics (mean, standard deviation [sd], median, interquartile range [iqr]) will be used to summarize change from baseline in the frequency of CD11a high PD-1+ CD8+ T cells following five doses of AGS-003-BLD.	Treatment visit 20 (Cycle 8) - After the 8th dose (3rd adjuvant) of AGS-003 - Bladder therapy, up to 12 weeks
Secondary	1-year survival rate		1 year
Secondary	2-year disease-free survival rate		2 years
Secondary	2-year survival rate		2 years
Secondary	Disease-free survival rate		1 year
Secondary	Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events	The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine adverse event patterns.	Up to 2 years
Secondary	Manufacturing success rate and successful manufacture of > 5 doses and administration of 1 or more doses of AGS-003-BLD	Descriptive statistics (frequency table) and histogram will be used to summarize the success rate.	Up 2 years
Secondary	Proportion of pathologic complete responses	Descriptive statistics (frequency table) and histogram will be used to summarize the pathologic complete response rate.	Up to 2 years
Secondary	Time to first metastatic lesion	Will be estimated using the Kaplan-Meier method.	Time from randomization to first recognition of metastases, assessed up to 2 years